[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0207706A - ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase - Google Patents

ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase

Info

Publication number
BR0207706A
BR0207706A BR0207706-0A BR0207706A BR0207706A BR 0207706 A BR0207706 A BR 0207706A BR 0207706 A BR0207706 A BR 0207706A BR 0207706 A BR0207706 A BR 0207706A
Authority
BR
Brazil
Prior art keywords
esters
dihydrofolate reductase
diaminoquinazoline
reductase inhibitors
inhibitors
Prior art date
Application number
BR0207706-0A
Other languages
English (en)
Inventor
Torbjoern Lundstedt
Anneli Haellgren
Per Andersson
Anders Hallberg
Malin Graffner Nordberg
Original Assignee
Melacure Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100694A external-priority patent/SE0100694D0/xx
Priority claimed from SE0200008A external-priority patent/SE0200008D0/xx
Application filed by Melacure Therapeutics Ab filed Critical Melacure Therapeutics Ab
Publication of BR0207706A publication Critical patent/BR0207706A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"éSTERES DE DIAMINOQUINAZOLINA PARA USO COMO INIBIDORES DA DIIDROFOLATO REDUTASE". A presente invenção refere-se aos compostos da fórmula (I), em que R~ 1~, R~ 2~, R~ 1~' e R~ 2~' são independentemente hidrogênio ou um grupo que libera a amina livre in vivo, R~ 6~ é uma fenila substituída ou um sistema de anéis de arila opcionalmente substituídos, bicíclicos ou tricíclicos, ou um sistema de anéis de heteroarila opcionalmente substituídos, mono, bi- ou tricíclicos, tendo utilidade como inibidores da diidrofolato redutase (DHFR) com propriedades farmacocinéticas favoráveis.
BR0207706-0A 2001-02-28 2002-02-28 ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase BR0207706A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0100694A SE0100694D0 (sv) 2001-02-28 2001-02-28 DHFR inhibitors
SE0200008A SE0200008D0 (sv) 2002-01-02 2002-01-02 New pharmaceutically compounds
PCT/GB2002/000888 WO2002068397A1 (en) 2001-02-28 2002-02-28 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors

Publications (1)

Publication Number Publication Date
BR0207706A true BR0207706A (pt) 2004-03-23

Family

ID=26655401

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207706-0A BR0207706A (pt) 2001-02-28 2002-02-28 ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase

Country Status (9)

Country Link
US (1) US20040092515A1 (pt)
EP (1) EP1366028A1 (pt)
JP (1) JP2004520414A (pt)
KR (1) KR20030086272A (pt)
BR (1) BR0207706A (pt)
CA (1) CA2439463A1 (pt)
IL (1) IL157597A0 (pt)
MX (1) MXPA03007699A (pt)
WO (1) WO2002068397A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032807A1 (en) * 2003-08-06 2005-02-10 Rosenwald Lindsay A. Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives
US20100222393A1 (en) * 2005-12-30 2010-09-02 Naresh Kumar Muscarinic receptor antagonists
GB0608822D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of DHFR
WO2008020042A1 (en) * 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases
US7550674B2 (en) 2007-02-22 2009-06-23 Nexans UTP cable
CA2766643C (en) 2009-07-08 2017-01-03 Dermira (Canada), Inc. Tofa analogs useful in treating dermatological disorders or conditions
CN110719960B (zh) * 2017-03-23 2024-03-08 梅哈里医学院 用于诊断和治疗炎性肠病的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108630A0 (en) * 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines

Also Published As

Publication number Publication date
JP2004520414A (ja) 2004-07-08
IL157597A0 (en) 2004-03-28
KR20030086272A (ko) 2003-11-07
WO2002068397A1 (en) 2002-09-06
EP1366028A1 (en) 2003-12-03
CA2439463A1 (en) 2002-09-06
MXPA03007699A (es) 2004-03-16
WO2002068397A8 (en) 2003-12-04
US20040092515A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
MX2013006101A (es) Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos.
MY146420A (en) Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
TW200740806A (en) Bridged N-cyclic sulfonamido inhibitors of gamma secretase
AR058700A1 (es) Compuestos heterociclicos como bloqueadores del canal de sodio epitelial
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
AR066691A1 (es) Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas.
MX2011005935A (es) Compuestos organicos.
GT200200069A (es) Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso
EA200971100A1 (ru) Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)
SG154435A1 (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
SG151250A1 (en) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
ECSP055910A (es) Nuevos acidos carboxilicos y sus esteres, medicamentos que contienen estos compuestos y procedimientos para su preparacion
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
RS51970B (en) TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS
ECSP088824A (es) Prolinamidas sustituidas, su preparación y su uso como medicamentos
MY152283A (en) Polo-like kinase inhibitirs
DE60314623D1 (de) Substituierte pyrazolopyrimidine
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
CL2011000784A1 (es) Compuestos derivados de 7-h-pirazoli[3,4-e]-diasepina-6(5h)-ona sustituidos; procedimiento de preparacion; composicion farmaceutica, utiles como agentes antibacteriales.
TN2011000429A1 (en) Derivatives of benzothiazines, preparation thereof and application thereof as drugs
BR0207706A (pt) ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase
DE502006008710D1 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
TW200724567A (en) Amide-containing polymers for rheology control

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4O, 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.